about
Determining the molecular mechanism of inactivation by chemical modification of triosephosphate isomerase from the human parasite Giardia lamblia: a study for antiparasitic drug designStructural and functional perturbation of Giardia lamblia triosephosphate isomerase by modification of a non-catalytic, non-conserved regionStructural effects of protein aging: terminal marking by deamidation in human triosephosphate isomerase.Induction of immunity in sheep to Fasciola hepatica with mimotopes of cathepsin L selected from a phage display library.The oxidative fermentation of ethanol in Gluconacetobacter diazotrophicus is a two-step pathway catalyzed by a single enzyme: alcohol-aldehyde Dehydrogenase (ADHa).Giardial triosephosphate isomerase as possible target of the cytotoxic effect of omeprazole in Giardia lambliaFactors that control the reactivity of the interface cysteine of triosephosphate isomerase from Trypanosoma brucei and Trypanosoma cruzi.An unusual triosephosphate isomerase from the early divergent eukaryote Giardia lamblia.Diarrhea in preschool children and Lactobacillus reuteri: a randomized controlled trial.Cloning, expression, purification and characterization of his-tagged human glucose-6-phosphate dehydrogenase: a simplified method for protein yield.Species-specific inhibition of Giardia lamblia triosephosphate isomerase by localized perturbation of the homodimer.Three-dimensional analysis of the arrangement of compact chromatin in the nucleus of G0 rat lymphocytes.The E104D mutation increases the susceptibility of human triosephosphate isomerase to proteolysis. Asymmetric cleavage of the two monomers of the homodimeric enzyme.Disulfide Bridges in the Mesophilic Triosephosphate Isomerase from Giardia lamblia Are Related to Oligomerization and ActivityLocalization of intranuclear RNA by electron microscopy in situ hybridization using a genomic DNA probeOn the molecular and cellular effects of omeprazole to further support its effectiveness as an antigiardial drug.
P50
Q27670984-8DCB42AB-8761-4FBA-A165-252504D17A27Q27679239-58B1CFFB-2AC7-41F9-8A14-E7F5DC66547FQ30373836-6B47352C-C341-48F3-B3C0-46E1B01D2141Q33371412-9ED37EB5-C146-4BC9-8415-6F2A4632F0C0Q41600977-B533690D-1ACA-404F-B523-FE8D43615B3CQ42116901-8EB0252B-4407-4D66-A26C-B8C72F14FC4FQ43547679-898F2DAA-01A2-461E-83E2-E53BE4DC5376Q44898256-25723B4B-3B80-43A1-B0D4-E3DFD66B00AEQ45381916-2085CE17-B029-46E8-AF62-C4813013D3B0Q46346066-7248A2A5-03C0-4FEC-B9F6-E2D42DFE2892Q46852674-C178291E-9F65-4F71-9AC0-342FA177E481Q48520955-1DAF48A9-3D23-4A9C-897F-8CC3D131D496Q53089326-FD7C94F6-45E9-4F2E-8DEA-AF0F31B70A01Q57881583-5A7B3336-0D73-46B6-9A32-9C2949DDC430Q64382028-FDE04EF7-4D15-4130-92B6-E68F02083E88Q64880222-A733DF58-3FAF-4206-8D31-A667827A6A89
P50
description
onderzoeker
@nl
researcher, ORCID id # 0000-0003-0470-1069
@en
name
Gabriel Lopez-Velazquez
@ast
Gabriel Lopez-Velazquez
@en
Gabriel Lopez-Velazquez
@es
Gabriel Lopez-Velazquez
@nl
type
label
Gabriel Lopez-Velazquez
@ast
Gabriel Lopez-Velazquez
@en
Gabriel Lopez-Velazquez
@es
Gabriel Lopez-Velazquez
@nl
prefLabel
Gabriel Lopez-Velazquez
@ast
Gabriel Lopez-Velazquez
@en
Gabriel Lopez-Velazquez
@es
Gabriel Lopez-Velazquez
@nl
P106
P1153
23109230700
P31
P496
0000-0003-0470-1069